Open access
Cost-Effectiveness of Perioperative Enfortumab Vedotin and Pembrolizumab for Bladder Cancer
Z. Su
Tyler S. Garman
Carlos A. Rivera López
Ruchika Talwar
R. Chelluri
B. Johnson
Hiten D. Patel
Akshay Sood
Armine K. Smith
N. Singla
Jean Hoffman-Censits
Sunil H. Patel
S. Daneshmand
Matthew E. Nielsen
T. Bivalacqua
S. Boorjian
Noah M. Hahn
Jeffrey P. Townsend
Max R. Kates
Medicine
Abstract
This economic evaluation assesses the health economic value, for a US Medicare payer, of adopting perioperative enfortumab vedotin plus pembrolizumab for treatment of cisplatin-ineligible patients with muscle-invasive bladder cancer.